ECTRIMS 2023 | Analysis of the diagnostic utility of cerebrospinal fluid MOG-IgG

Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine, Rochester, MN, discusses the assessment of myelin oligodendrocyte glycoprotein (MOG)-IgG primarily in serum and, more recently, in CSF, with a particular emphasis on understanding its implications for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) diagnosis. While many studies have been conducted outside the US, there’s a growing need to understand the role of CSF MOG-IgG, especially in light of the new 2023 MOGAD diagnostic criteria. The study involved analyzing 447 CSF samples across different patient groups. Key findings included a high correlation between serum and CSF MOG-IgG and the occurrence of isolated CSF positivity. Dr Redenbaugh suggests that CSF MOG-IgG can offer clarity in ambiguous low-positive serum cases and recommends judicious testing to avoid high false positivity. The conclusion emphasizes the value of multicenter studies to better understand these patients’ disease phenotypes. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.